Childhood Asthma Management Program

Childhood Asthma Management Program. The Childhood Asthma Management Program was a landmark, multi-center clinical trial sponsored by the National Heart, Lung, and Blood Institute to evaluate the long-term effects of daily medication in children with mild-to-moderate asthma. Conducted over several years, it aimed to determine whether continuous anti-inflammatory therapy could improve lung growth and prevent irreversible airway damage. The study's findings, published in the New England Journal of Medicine, fundamentally shaped pediatric asthma guidelines and treatment paradigms worldwide.

Background and Development

The program was conceived in the early 1990s amid growing concern within the American Thoracic Society and the Global Initiative for Asthma about the potential long-term consequences of childhood asthma on pulmonary function. Prior research, including studies from the Tucson Children's Respiratory Study, suggested that early airway inflammation might lead to permanent deficits. Key investigators, including Dr. Robert Strunk and Dr. Stanley Szefler, helped design the protocol with support from the National Institutes of Health. The trial was launched to address critical gaps identified in earlier research from institutions like the Harvard Medical School and the Johns Hopkins Hospital, specifically the need for long-term data on corticosteroid use in children.

Study Design and Methodology

This randomized, double-blind, placebo-controlled trial enrolled over 1,000 children aged 5 to 12 years from eight clinical centers across the United States, including sites affiliated with the University of Washington and the Brigham and Women's Hospital. Participants were randomly assigned to receive twice-daily treatment with inhaled budesonide, nedocromil, or a placebo for a period of four to six years. The primary outcome measures were spirometric values, particularly the forced expiratory volume in one second, assessed regularly at clinics like the National Jewish Health center. Secondary outcomes included asthma symptoms, hospitalizations, and use of rescue medications like albuterol, with data coordinated by the Data and Safety Monitoring Board.

Key Findings and Outcomes

The study, whose results were announced at an American Academy of Allergy, Asthma & Immunology meeting, found that daily budesonide significantly improved asthma control, reducing symptoms and the need for prednisone bursts compared to placebo. However, it did not demonstrate a significant improvement in the primary endpoint of post-bronchodilator FEV1 growth over the treatment period. The nedocromil group showed more modest benefits in symptom control. Notably, children in the budesonide group had a small but statistically significant reduction in growth velocity, approximately 1 centimeter per year, a finding that prompted widespread discussion at forums like the European Respiratory Society congress.

Clinical Recommendations and Impact

Based on its evidence, the program led to revised guidelines from the National Asthma Education and Prevention Program and influenced international standards from the British Thoracic Society. It provided strong support for the use of inhaled corticosteroids as first-line controller therapy for persistent asthma in children, a recommendation later endorsed by the World Health Organization. The findings also prompted caution regarding growth monitoring, leading to new protocols at institutions like the Mayo Clinic and Cincinnati Children's Hospital Medical Center. The trial's data were instrumental in the FDA's evaluations of pediatric asthma medications and informed treatment algorithms published in journals like The Lancet.

Long-term Follow-up and Legacy

Extended follow-up studies, such as the CAMP Continuation Study, tracked participants into adulthood, providing invaluable data on the natural history of asthma. These follow-ups, presented at the American College of Chest Physicians conference, showed that differences in lung function and growth attenuation did not persist into late adolescence. The program's rich dataset has been used for numerous ancillary genetic and epidemiological studies by researchers at the Channing Laboratory and the University of Chicago. Its legacy endures as a model for long-term pediatric clinical trials, influencing subsequent major studies like the Prevention of Early Asthma in Kids trial and the Asthma Clinical Research Network.

Category:Clinical trials Category:Pediatrics Category:Respiratory diseases